{"id":50918,"date":"2022-11-16T00:02:08","date_gmt":"2022-11-15T23:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/"},"modified":"2022-11-16T00:02:08","modified_gmt":"2022-11-15T23:02:08","slug":"twist-bioscience-addresses-misleading-short-seller-report","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/","title":{"rendered":"Twist Bioscience Addresses Misleading Short-Seller Report"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time<\/i>\n<\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twistbioscience.com%2F&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=Twist+Bioscience+Corporation&amp;index=1&amp;md5=7dceb305655df21d52980e1cd6c7403a\" rel=\"nofollow noopener\" shape=\"rect\">Twist Bioscience Corporation<\/a> (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a misleading short-seller report issued by Scorpion Capital.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/5\/Twist_Bioscience_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg\"><\/a><\/p>\n<p>\nTwist believes that the short-seller report issued by Scorpion Capital is highly misleading, with many distortions and inaccuracies. Unlike the author of the short-seller report, Twist is a public company, and is committed to communicating truthfully, creating value for all shareholders, and being good stewards of capital. In addition, Twist\u2019s <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twistbioscience.com%2Fcompany%2Fesg&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=inaugural+ESG+report&amp;index=2&amp;md5=f009f6421efff4fa9aa4e4d0a21974dc\" rel=\"nofollow noopener\" shape=\"rect\">inaugural ESG report<\/a> details the company\u2019s environmental, social and governance practices at length, which Twist fully stands behind.\n<\/p>\n<p>\nTwist remains focused on its mission to improve health and sustainability by manufacturing DNA at scale and on growing its business, including shipping product from the Factory of the Future in January 2023.\n<\/p>\n<p>\nTwist will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 30, 2022, before the opening of the market on Friday, November 18, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company\u2019s business.\n<\/p>\n<p>\nThe conference call will be webcast live through the Investor Relations section under the \u201cCompany\u201d tab at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.twistbioscience.com%2F&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=www.twistbioscience.com&amp;index=3&amp;md5=a437bb66fe6ab99e3b2392c225409cb3\" rel=\"nofollow noopener\" shape=\"rect\">www.twistbioscience.com<\/a>. Those parties interested in participating via telephone must register on the Company\u2019s Investor Relations website or by clicking <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBI633d4b3a2ff540a7ab63a268fb3b72ac&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=6076e1fb51786fcdcf98faf2ceb6f3e9\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.\n<\/p>\n<p>\n<b>About Twist Bioscience Corporation<\/b>\n<\/p>\n<p>\nTwist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by \u201cwriting\u201d DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.\n<\/p>\n<p>\nFollow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Ftwistbioscience&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=5dacc51b0f4ff5070bed947882d5f2de\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> | <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FTwistBioscience%2F&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=2e72cfb6ca59c998b750ab79ad6d8fcc\" rel=\"nofollow noopener\" shape=\"rect\">Facebook<\/a> | <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftwist-bioscience%2F&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=ff0afb07c1e94e894ae6c7f09f528d1f\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> | <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fc%2FTwistBioscience&amp;esheet=52970456&amp;newsitemid=20221115006517&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=b60fd4bc328a3b76290e1b1460128154\" rel=\"nofollow noopener\" shape=\"rect\">YouTube<\/a>\n<\/p>\n<p>\n<b>Legal Notice Regarding Forward-Looking Statements<\/b>\n<\/p>\n<p>\nThis press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience\u2019s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience\u2019s business in general, see Twist Bioscience\u2019s risk factors set forth in Twist Bioscience\u2019s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For Twist Bioscience:<\/b><br \/>Angela Bitting<br \/>\n<br \/>SVP, Corporate Affairs<br \/>\n<br \/>925- 202-6211<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:a&#98;&#105;&#116;&#116;&#105;&#110;&#103;&#64;&#116;&#119;&#x69;&#x73;&#x74;&#x62;&#x69;&#x6f;&#x73;&#x63;&#x69;&#x65;&#x6e;&#x63;&#x65;&#x2e;&#x63;om\" rel=\"nofollow noopener\" shape=\"rect\">&#97;&#x62;&#105;&#x74;&#116;&#x69;&#110;&#x67;&#64;&#x74;&#119;&#x69;s&#x74;b&#x69;o&#x73;c&#x69;e&#x6e;c&#101;&#x2e;&#99;&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50918","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Twist Bioscience Addresses Misleading Short-Seller Report - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Twist Bioscience Addresses Misleading Short-Seller Report - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T23:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Twist Bioscience Addresses Misleading Short-Seller Report\",\"datePublished\":\"2022-11-15T23:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/\"},\"wordCount\":657,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006517\\\/en\\\/1121919\\\/21\\\/Twist_Bioscience_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/\",\"name\":\"Twist Bioscience Addresses Misleading Short-Seller Report - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006517\\\/en\\\/1121919\\\/21\\\/Twist_Bioscience_Logo.jpg\",\"datePublished\":\"2022-11-15T23:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006517\\\/en\\\/1121919\\\/21\\\/Twist_Bioscience_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221115006517\\\/en\\\/1121919\\\/21\\\/Twist_Bioscience_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/twist-bioscience-addresses-misleading-short-seller-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Twist Bioscience Addresses Misleading Short-Seller Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Twist Bioscience Addresses Misleading Short-Seller Report - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/","og_locale":"en_US","og_type":"article","og_title":"Twist Bioscience Addresses Misleading Short-Seller Report - Pharma Trend","og_description":"Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today addressed a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-15T23:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Twist Bioscience Addresses Misleading Short-Seller Report","datePublished":"2022-11-15T23:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/"},"wordCount":657,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/","url":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/","name":"Twist Bioscience Addresses Misleading Short-Seller Report - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg","datePublished":"2022-11-15T23:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221115006517\/en\/1121919\/21\/Twist_Bioscience_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/twist-bioscience-addresses-misleading-short-seller-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Twist Bioscience Addresses Misleading Short-Seller Report"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50918"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50918\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}